Evidence map›Paper›PMID 39041269›Full record

ReviewCurrent pharmaceutical design2024

Role of Natural Products against the Spread of SARS-CoV-2 by Inhibition of ACE-2 Receptor: A Review.

Krishana Kumar Sharma, Shoma Devi, Dharmendra Kumar, Zeeshan Ali, Nishat Fatma, Raghvendra Misra, Gajendra Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Krishana Kumar SharmaTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001 (UP), India.
Shoma DeviDepartment of Zoology, Krishna College of Science & Information Technology, Bijnor 246701 (UP), India.
Dharmendra KumarScience Branch, Pt. Deendayal Upadhyay Institute of Archaeology, Archaeological Survey of India, Greater Noida 201013, India.
Zeeshan AliTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001 (UP), India.
Nishat FatmaTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001 (UP), India.
Raghvendra MisraTeerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001 (UP), India.
Gajendra KumarDepartment of Chemistry, Constituent Government College, MJP Rohilkhand University, Bareilly, Hasanpur, Amroha 244241 (UP), India.ORCID 0000-0002-1423-4655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A unique extreme acute breathing syndrome emerged in China and spread rapidly globally due to a newly diagnosed human coronavirus and declared a pandemic. COVID-19 was formally named by WHO, and the Global Committee on Taxonomy referred to it as extreme Acute respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Currently there is no efficient method to control the extent of SARS-CoV-2 other than social distancing and hygiene activities. This study aims to present a simple medicinal strategy for combating fatal viral diseases like COVID-19 with minimum effort and intervention. Different Ayurveda medicines (

Indexed as

Angiotensin-Converting Enzyme 2Antiviral AgentsBiological ProductsCOVID-19COVID-19 Drug TreatmentSARS-CoV-2AnimalsCurcuminHumansACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsBiological ProductsCurcumin1-piperoylpiperidine2019-nCoVACE-2catechincurcumininhibitorsTMPRSS2.

Identifiers

PMID39041269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.